SCHEMBL10126037

SCHEMBL10126037

Cc1ccc(C)c2oc(-c3ccc(-c4ccc(-c5nc6ccccc6nc5-c5ccc(-c6ccc(-c7nc8c(C)ccc(C)c8o7)cc6)cc5)cc4)cc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.46
RARA P10276 3/20 0.43
RARB P10826 3/20 0.43
RARG P13631 3/20 0.43
PDE10A Q9Y233 1/20 0.41
DHODH Q02127 1/20 0.40
KDM4E B2RXH2 6/20 0.40
ALDH1A1 P00352 5/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125872 0.97 TDP1 (0.51) TDP1RARARARBRARGPDE10A
SCHEMBL10126027 0.84 DHODH (0.51) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL18873093 0.82 RARA (0.50) RARARARBRARGDHODHKDM4E
SCHEMBL10125851 0.81 DHODH (0.56) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL10126032 0.81 CEPT1 (0.48) TDP1PDE10AKDM4EALDH1A1RAB9A
SCHEMBL17059011 0.79 RARA (0.50) RARARARBRARGKDM4EALDH1A1
SCHEMBL10125860 0.79 TDP1 (0.50) TDP1PDE10ADHODHKDM4EALDH1A1
SCHEMBL10125992 0.77 NPC1 (0.56) KDM4EALDH1A1RAB9APOLBMAPT
SCHEMBL13621028 0.77 RARA (0.46) RARARARBRARGDHODHKDM4E
SCHEMBL10126040 0.76 AKT1 (0.41) TDP1DHODHKDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 TDP1 2069/4885RARA 1265/4885RARB 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.